Articles tagged with Combination Therapies
A large clinical trial found that hormone replacement therapy with estrogen and progestin did not increase or decrease the risk of stroke among postmenopausal women with heart disease. The study's lead author cautioned that the results may not apply to all women taking hormone therapy, and more research is needed.
A clinical trial of Mylotarg found disease remission in 34% of patients under 60 and 26% of those over 60, with a median overall survival of 5.9 months. No significant differences were seen in adverse events between age groups.
Researchers found that combining radiation therapy with androgen suppression therapy significantly reduced the risk of PSA failure in men with intermediate- and high-risk prostate cancer. The treatment showed efficacy even in low-risk patients, suggesting a potential benefit for all early-stage prostate cancer patients.
A study of postmenopausal women in Los Angeles County found that long-term use of hormone replacement therapy combining estrogen and progestin increases breast cancer risk by 24%. The risk was highest for sequential therapy, but continuous combined therapy showed lower risks. Researchers suggest lowering doses to decrease disease risk.
A study suggests that triple-drug treatment regimens are superior to less intensive therapies in maintaining HIV suppression. Researchers found that patients who switched from three-drug to two- or one-drug treatment regimens were more likely to experience a resurgence in their HIV levels.
A large-scale study shows that estrogen replacement therapy, with or without progestin, consistently and sustainably reduces plasma lipoprotein (a) concentrations, a high-risk factor for heart attacks and strokes. The results also confirm hormone therapy's broad-scale impact on cholesterol metabolism.
Researchers studied 1,947 women and found that taking progestin with estrogen therapy reduces risk of endometrial cancer by four-fold, but risks increase with shorter progestin cycles. Women who took combination therapy for over five years had a higher risk of endometrial cancer compared to non-users.